Aripiprazole Once-Monthly for the Treatment of Adult Patients in the Earlier Stages of Bipolar I Disorder: A Post Hoc Analysis of Clinical Trial Data.

Bell Lynum, Karimah S.; Zhang, Zhen; Castro, Christine F.; Patel, Mehul; Tohen, Mauricio

Introduction: The efficacy and safety of aripiprazole once-monthly 400 mg (AOM 400) as maintenance monotherapy treatment for bipolar I disorder (BP-I) were demonstrated in a double-blind, placebo-controlled, 52-week randomized withdrawal trial (NCT01567527). This post hoc analysis of data from NCT01567527 evaluated the efficacy of AOM 400 in the earlier BP-I population. Methods: Patients within the first quartile of the dataset according to age (18–32 years: AOM 400, n=36; placebo, n=34) or disease duration (≤4.6 years: AOM 400, n=33; placebo, n=34) were considered to be in the earlier stages of BP-I, and were included. The primary outcome was time from randomization to recurrence of any mood episode, defined as meeting any one of several predetermined criteria, including Young Mania Rating Scale (YMRS) total score ≥15 or clinical worsening. Results: Time to recurrence of any mood episode was significantly delayed with AOM 400 versus placebo in patients aged 18–32 years (hazard ratio [HR]: 2.462 [95% confidence interval (CI): 1.092, 5.547]; p<0.05) and in patients with a disease duration ≤4.6 years (HR: 3.207 [95% CI: 1.346, 7.645]; p<0.01). Further analysis suggested that the benefit of AOM 400 versus placebo was driven by a significantly lower proportion of patients experiencing a YMRS total score ≥15 (18–32 years: 5.60% versus 44.10%, p<0.001; disease duration ≤4.6 years: 6.10% versus 41.20%, p<0.01) or clinical worsening (18–32 years: 8.30% versus 38.20%, p<0.01; disease duration ≤4.6 years: 6.10% versus 38.20%, p<0.01). Conclusion: The efficacy of AOM 400 was demonstrated in the earlier BP-I population. Study registration number: NCT01567527 (ClinicalTrials.gov) The data in this poster were originally presented at Psych Congress, held on 6–10th September 2023 in Nashville, TN, USA. Funding: Otsuka Pharmaceutical Development & Commercialization Inc. (Princeton, NJ, USA) and Lundbeck LLC (Deerfield, IL, USA).

DISEASE duration; PATIENTS' attitudes; BIPOLAR disorder; CONFIDENCE intervals; DATA analysis

CNS Spectrums: The International Journal of Neuropsychiatric Medicine, 2024, Vol 29, Issue 5, p483

1092-8529

Academic Journal

10.1017/S1092852924001330